Crestor

Hyperlipoproteinemia Type III, Hardening of the Arteries, Hyperlipidemia + 22 more

Treatment

16 FDA approvals

20 Active Studies for Crestor

What is Crestor

Rosuvastatin

The Generic name of this drug

Treatment Summary

Rosuvastatin, also known as Crestor, is a medication used to reduce the risk of cardiovascular disease by lowering cholesterol levels in the body. It belongs to a class of drugs called statins, which block the liver's production of cholesterol. It is commonly prescribed following cardiovascular events and to people with a moderate to high risk of developing cardiovascular disease. Rosuvastatin is known to be the most potent statin drug. It is generally effective and well-tolerated with minimal side effects or long-term effects. It is also less likely to interact with other medications compared to some other statins.

Crestor

is the brand name

image of different drug pills on a surface

Crestor Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Crestor

Rosuvastatin

2003

441

Approved as Treatment by the FDA

Rosuvastatin, otherwise known as Crestor, is approved by the FDA for 16 uses including primary Hyperlipidemia and Homozygous Familial Hypercholesterolaemia (HoFH) .

primary Hyperlipidemia

Homozygous Familial Hypercholesterolaemia (HoFH)

Hypertriglyceridemias

Coronary Artery Disease (CAD)

Helps manage Coronary Artery Disease (CAD)

Dyslipidemias

Dysbetalipoproteinemia

Heart Disease

Heterozygous Familial Hypercholesterolemia (HeFH)

Hyperlipidemia

Homozygous Familial Hypercholesterolemia

Hypertriglyceridemia

Hypercholesterolemia

Hardening of the Arteries

Helps manage Atherosclerosis

Coronary Disease

Helps manage Coronary Artery Disease (CAD)

Atherosclerotic Cardiovascular Diseases

Hyperlipoproteinemia Type III

Effectiveness

How Crestor Affects Patients

Rosuvastatin is a drug used to lower cholesterol. It reduces total cholesterol, LDL-cholesterol, Apolipoprotein B, non-HDL-cholesterol, and triglyceride levels while increasing HDL-cholesterol levels. High LDL-cholesterol, low HDL-cholesterol, and high triglyceride levels can lead to an increased risk of atherosclerosis and cardiovascular disease. Taking rosuvastatin can reduce this risk and decrease the chances of having a major cardiovascular event such as a heart attack, stroke, or coronary death. However, there is a risk of muscle pain, liver enzyme abnormalities, and changes in

How Crestor works in the body

Rosuvastatin works by blocking an enzyme that helps create cholesterol. When this happens, the liver produces more low density lipoprotein (LDL) receptors, which help pull LDL out of the blood. This leads to a decrease in LDL and very low density lipoprotein (VLDL) in the bloodstream. Studies have also shown that rosuvastatin has additional benefits outside of just cholesterol-lowering, such as improving the stability of atherosclerotic plaques, reducing oxidative stress, and inhibiting the thrombogenic response. It also affects leukocyte trafficking and T cell activation by binding to a

When to interrupt dosage

The measure of Crestor is contingent upon the diagnosed state, such as Diet, Dysbetalipoproteinemia and Heart Disease. The amount of dosage differs, as per the procedure of administration laid out in the table below.

Condition

Dosage

Administration

Hyperlipoproteinemia Type III

, 10.0 mg, 20.0 mg, 40.0 mg, 5.0 mg, 5.2 mg, 20.8 mg, 41.7 mg, 10.4 mg

Oral, , Tablet, film coated - Oral, Tablet, film coated, Tablet, coated, Tablet, coated - Oral, Tablet - Oral, Tablet, Capsule, Capsule - Oral

Hardening of the Arteries

, 10.0 mg, 20.0 mg, 40.0 mg, 5.0 mg, 5.2 mg, 20.8 mg, 41.7 mg, 10.4 mg

Oral, , Tablet, film coated - Oral, Tablet, film coated, Tablet, coated, Tablet, coated - Oral, Tablet - Oral, Tablet, Capsule, Capsule - Oral

Hyperlipidemia

, 10.0 mg, 20.0 mg, 40.0 mg, 5.0 mg, 5.2 mg, 20.8 mg, 41.7 mg, 10.4 mg

Oral, , Tablet, film coated - Oral, Tablet, film coated, Tablet, coated, Tablet, coated - Oral, Tablet - Oral, Tablet, Capsule, Capsule - Oral

Coronary Disease

, 10.0 mg, 20.0 mg, 40.0 mg, 5.0 mg, 5.2 mg, 20.8 mg, 41.7 mg, 10.4 mg

Oral, , Tablet, film coated - Oral, Tablet, film coated, Tablet, coated, Tablet, coated - Oral, Tablet - Oral, Tablet, Capsule, Capsule - Oral

Primary Hypercholesterolemia

, 10.0 mg, 20.0 mg, 40.0 mg, 5.0 mg, 5.2 mg, 20.8 mg, 41.7 mg, 10.4 mg

Oral, , Tablet, film coated - Oral, Tablet, film coated, Tablet, coated, Tablet, coated - Oral, Tablet - Oral, Tablet, Capsule, Capsule - Oral

Physical Activity

, 10.0 mg, 20.0 mg, 40.0 mg, 5.0 mg, 5.2 mg, 20.8 mg, 41.7 mg, 10.4 mg

Oral, , Tablet, film coated - Oral, Tablet, film coated, Tablet, coated, Tablet, coated - Oral, Tablet - Oral, Tablet, Capsule, Capsule - Oral

Cardiovascular Events

, 10.0 mg, 20.0 mg, 40.0 mg, 5.0 mg, 5.2 mg, 20.8 mg, 41.7 mg, 10.4 mg

Oral, , Tablet, film coated - Oral, Tablet, film coated, Tablet, coated, Tablet, coated - Oral, Tablet - Oral, Tablet, Capsule, Capsule - Oral

Diet

, 10.0 mg, 20.0 mg, 40.0 mg, 5.0 mg, 5.2 mg, 20.8 mg, 41.7 mg, 10.4 mg

Oral, , Tablet, film coated - Oral, Tablet, film coated, Tablet, coated, Tablet, coated - Oral, Tablet - Oral, Tablet, Capsule, Capsule - Oral

cholesterol

, 10.0 mg, 20.0 mg, 40.0 mg, 5.0 mg, 5.2 mg, 20.8 mg, 41.7 mg, 10.4 mg

Oral, , Tablet, film coated - Oral, Tablet, film coated, Tablet, coated, Tablet, coated - Oral, Tablet - Oral, Tablet, Capsule, Capsule - Oral

Lipid-Lowering Therapy

, 10.0 mg, 20.0 mg, 40.0 mg, 5.0 mg, 5.2 mg, 20.8 mg, 41.7 mg, 10.4 mg

Oral, , Tablet, film coated - Oral, Tablet, film coated, Tablet, coated, Tablet, coated - Oral, Tablet - Oral, Tablet, Capsule, Capsule - Oral

Hypertensive disease

, 10.0 mg, 20.0 mg, 40.0 mg, 5.0 mg, 5.2 mg, 20.8 mg, 41.7 mg, 10.4 mg

Oral, , Tablet, film coated - Oral, Tablet, film coated, Tablet, coated, Tablet, coated - Oral, Tablet - Oral, Tablet, Capsule, Capsule - Oral

Venous Thrombosis

, 10.0 mg, 20.0 mg, 40.0 mg, 5.0 mg, 5.2 mg, 20.8 mg, 41.7 mg, 10.4 mg

Oral, , Tablet, film coated - Oral, Tablet, film coated, Tablet, coated, Tablet, coated - Oral, Tablet - Oral, Tablet, Capsule, Capsule - Oral

High Cardiovascular Risk

, 10.0 mg, 20.0 mg, 40.0 mg, 5.0 mg, 5.2 mg, 20.8 mg, 41.7 mg, 10.4 mg

Oral, , Tablet, film coated - Oral, Tablet, film coated, Tablet, coated, Tablet, coated - Oral, Tablet - Oral, Tablet, Capsule, Capsule - Oral

Hypertriglyceridemia

, 10.0 mg, 20.0 mg, 40.0 mg, 5.0 mg, 5.2 mg, 20.8 mg, 41.7 mg, 10.4 mg

Oral, , Tablet, film coated - Oral, Tablet, film coated, Tablet, coated, Tablet, coated - Oral, Tablet - Oral, Tablet, Capsule, Capsule - Oral

Heart Disease

, 10.0 mg, 20.0 mg, 40.0 mg, 5.0 mg, 5.2 mg, 20.8 mg, 41.7 mg, 10.4 mg

Oral, , Tablet, film coated - Oral, Tablet, film coated, Tablet, coated, Tablet, coated - Oral, Tablet - Oral, Tablet, Capsule, Capsule - Oral

Hypercholesterolemia

, 10.0 mg, 20.0 mg, 40.0 mg, 5.0 mg, 5.2 mg, 20.8 mg, 41.7 mg, 10.4 mg

Oral, , Tablet, film coated - Oral, Tablet, film coated, Tablet, coated, Tablet, coated - Oral, Tablet - Oral, Tablet, Capsule, Capsule - Oral

Major Adverse Cardiovascular Events

, 10.0 mg, 20.0 mg, 40.0 mg, 5.0 mg, 5.2 mg, 20.8 mg, 41.7 mg, 10.4 mg

Oral, , Tablet, film coated - Oral, Tablet, film coated, Tablet, coated, Tablet, coated - Oral, Tablet - Oral, Tablet, Capsule, Capsule - Oral

Hypertensive disease

, 10.0 mg, 20.0 mg, 40.0 mg, 5.0 mg, 5.2 mg, 20.8 mg, 41.7 mg, 10.4 mg

Oral, , Tablet, film coated - Oral, Tablet, film coated, Tablet, coated, Tablet, coated - Oral, Tablet - Oral, Tablet, Capsule, Capsule - Oral

Dyslipidemias

, 10.0 mg, 20.0 mg, 40.0 mg, 5.0 mg, 5.2 mg, 20.8 mg, 41.7 mg, 10.4 mg

Oral, , Tablet, film coated - Oral, Tablet, film coated, Tablet, coated, Tablet, coated - Oral, Tablet - Oral, Tablet, Capsule, Capsule - Oral

Atherosclerotic Cardiovascular Diseases

, 10.0 mg, 20.0 mg, 40.0 mg, 5.0 mg, 5.2 mg, 20.8 mg, 41.7 mg, 10.4 mg

Oral, , Tablet, film coated - Oral, Tablet, film coated, Tablet, coated, Tablet, coated - Oral, Tablet - Oral, Tablet, Capsule, Capsule - Oral

Warnings

Crestor Contraindications

Condition

Risk Level

Notes

Breast Milk Production

Do Not Combine

Pulse Frequency

Do Not Combine

Liver Failure, Acute

Do Not Combine

There are 20 known major drug interactions with Crestor.

Common Crestor Drug Interactions

Drug Name

Risk Level

Description

Astemizole

Major

The metabolism of Astemizole can be decreased when combined with Rosuvastatin.

Axitinib

Major

The metabolism of Axitinib can be decreased when combined with Rosuvastatin.

Cabazitaxel

Major

The metabolism of Cabazitaxel can be decreased when combined with Rosuvastatin.

Carbamazepine

Major

The metabolism of Carbamazepine can be decreased when combined with Rosuvastatin.

Clonidine

Major

The metabolism of Clonidine can be decreased when combined with Rosuvastatin.

Crestor Toxicity & Overdose Risk

Generally, this drug is safe to take. Common side effects may include muscle pain, constipation, exhaustion, stomach ache, and nausea. Less common side effects include damage to the muscles or liver. Asian patients may need a lower dosage to avoid toxicity, as studies show they absorb the drug more quickly than those of Caucasian descent.

image of a doctor in a lab doing drug, clinical research

Crestor Novel Uses: Which Conditions Have a Clinical Trial Featuring Crestor?

94 studies are currently examining the utility of Crestor in providing Postoperative Thromboembolism prevention, Hypertriglyceridemias management and Cardiovascular Event mitigation.

Condition

Clinical Trials

Trial Phases

other lipid-lowering therapies not suitable

0 Actively Recruiting

Diet

5 Actively Recruiting

Not Applicable, Phase 1

Hypercholesterolemia

4 Actively Recruiting

Phase 1, Phase 3

Hypertensive disease

3 Actively Recruiting

Not Applicable, Phase 3

Coronary Disease

1 Actively Recruiting

Not Applicable

Hardening of the Arteries

18 Actively Recruiting

Not Applicable, Phase 4, Phase 2, Phase 3

Homozygous Familial Hypercholesterolemia

2 Actively Recruiting

Phase 3

Cardiovascular Events

4 Actively Recruiting

Not Applicable

Dyslipidemias

1 Actively Recruiting

Phase 2

Primary Prevention of Cardiovascular Diseases

1 Actively Recruiting

Not Applicable

Hyperlipoproteinemia Type III

0 Actively Recruiting

Atherosclerotic Cardiovascular Diseases

12 Actively Recruiting

Phase 3, Not Applicable, Phase 2, Phase 4

Drug Combinations

0 Actively Recruiting

cholesterol

4 Actively Recruiting

Phase 3, Not Applicable

Hypertensive disease

27 Actively Recruiting

Not Applicable, Phase 1, Phase 2, Phase 3

Primary Hypercholesterolemia

8 Actively Recruiting

Phase 3, Phase 2, Not Applicable

Major Adverse Cardiovascular Events

0 Actively Recruiting

Hyperlipidemia

0 Actively Recruiting

Heart Disease

37 Actively Recruiting

Not Applicable, Phase 3, Phase 2, Phase 1, Phase 4, Early Phase 1

diet and exercise

0 Actively Recruiting

Crestor Reviews: What are patients saying about Crestor?

5

Patient Review

11/28/2021

Crestor for High Cholesterol

Crestor was my third try at a statin medication, and it finally worked without any awful side effects. I take a very low dose, but it's kept my cholesterol in the normal range for about ten years now.

3.3

Patient Review

10/10/2022

Crestor for Increased Triglycerides and Cholesterol

I developed shoulder pain a few months after starting to take Crestor 10mg. After I stopped taking the medication for a short while, the pain went away. My doctor told me to slowly start taking it again because my numbers were excellent. However, recently after going back on the medication, I've been having gastrointestinal issues and diarrhea. Has anyone else experienced this?

2.7

Patient Review

3/28/2022

Crestor for Treatment to Prevent a Heart Attack

I developed bells palsy after just three months of taking Crestor, which my doctor had prescribed for high cholesterol. After doing some research, I found that many statin drugs are linked to causing this condition. For me, the benefits did not outweigh the risks.

2.3

Patient Review

8/30/2022

Crestor for High Cholesterol

After three years of taking this medication, it left me with muscle problems that required the help of a cane to walk. Once I stopped taking it, though, I was able to walk just fine within five days.

2.3

Patient Review

8/25/2022

Crestor for High Cholesterol

I've only been taking this medication for a short while, but the leg pain it's caused is unbearable. I may have to stop taking it as a result.

2

Patient Review

7/17/2022

Crestor for Treatment to Prevent a Heart Attack

Crestor caused me so much pain in my knees and hips. I couldn't even walk without being in agony. Thankfully, I stopped taking it after two months. Do your research before starting any medication!

1.7

Patient Review

8/15/2022

Crestor for Increased Triglycerides and Cholesterol

I've been experiencing a range of troubling side effects since taking this medication, including forgetting words, losing things multiple times per day, and muscle pain and weakness. I'm going to stop taking the drug today in hopes that my symptoms will improve.

1.3

Patient Review

11/27/2021

Crestor for Slow Progression of Disease of the Arteries of the Heart

I was not informed of the possible side effects of this medication. I have been taking Crestor for seven weeks and have noticed weakness in my quadriceps, fasciculations in my right leg, and increased back pain. My blood sugar has also risen with no prior history of diabetes. I stopped taking the medication nine days ago and am still waiting to see if the side effects are reversible.

1

Patient Review

8/15/2022

Crestor for Increased Triglycerides and Cholesterol

This drug has caused me a lot of problems. I've forgotten words mid sentence, have had severe leg pain and muscle loss, and become much more irritable. My gums have also started to deteriorate; this is on top of sugar cravings and other issues. If you're considering taking this drug, please weigh the pros and cons very carefully.

1

Patient Review

8/15/2022

Crestor for Increased Triglycerides and Cholesterol

I felt so dizzy and in pain that I could barely move. My mind was fuzzy and it was hard to communicate. The pain was unbearable. I'd rather control my ldl through diet and exercise than take this again.

1

Patient Review

12/4/2021

Crestor for Prevention of Transient Ischemic Attacks

I have been on this medication for nine months and it has caused me to be hospitalized six times. The side effects are severe dizziness, heart palpitations, high blood pressure, ankle pain, headaches, and flu-like symptoms. I stopped taking the medication and almost all of the symptoms went away. All of the doctors thought I was crazy. Do not ever take this medication!
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about crestor

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the most common side effect of Crestor?

"Common side effects of Crestor include headaches, muscle aches and pains, abdominal pain, weakness, and nausea. Other side effects that have been reported include memory loss and confusion. If you experience any side effects, tell your doctor."

Answered by AI

What does Crestor do to your body?

"Rosuvastatin may also be used to prevent certain types of heart problems, and to reduce the risk of stroke and heart attack.

Rosuvastatin is used to lower bad cholesterol, raise good cholesterol, and prevent heart problems."

Answered by AI

What foods should be avoided when taking Crestor?

"Do not eat foods that are high in fat or cholesterol as it will make the rosuvastatin less effective. Do not drink alcohol as it will raise triglyceride levels and may cause liver damage. Some antacids can reduce the body's ability to absorb rosuvastatin."

Answered by AI

Should I take Crestor at night?

"You can take CRESTOR at any time of day, with or without food."

Answered by AI

Clinical Trials for Crestor

Image of Miles Square Health Center Chicago in Chicago, United States.

Food is Medicine for High Blood Pressure and Obesity

Any Age
All Sexes
Chicago, IL

The goal of this clinical trial is to treat both hypertension and obesity in adults using a food is medicine framework. Participants will be randomized 1:1 to FIM+DASH or usual-care control. The 24-week trial includes a 12-week FIM+DASH intervention followed by a 12-week maintenance period and leverages existing partnerships with community-based organizations for home food delivery and culinary skill-skill building. The main questions it aims to answer are: (1) What is the effect of FIM+DASH vs. usual care control on blood pressure? (2) What is the effect of FIM+DASH vs. usual care control on DASH diet adherence (diet quality), body weight, and waist circumference? (3) How to identify factors associated with the sustainability and scalability of FIM+DASH in real-world settings?

Phase 2
Waitlist Available

Miles Square Health Center Chicago (+3 Sites)

Image of Mumford Professional Centre in Halifax, Canada.

Remote Monitoring for Cardiovascular Disease

18+
All Sexes
Halifax, Canada

The goal of this interventional study is to evaluate the implementation, usability, and clinical outcomes of a wearable medical-grade device in a virtual Cardiac Rehabilitation (CR) program, titled HEARTS in Sync. The question guiding this study is: Do patient clinical outcomes differ between those who use the CardioWatch 287-2 during the HEARTS in Sync program as compared to those who participate without using the CardioWatch 287-2? The comparison will happen between two non-randomized groups of patients who are enrolled in the HEARTS in Sync virtual CR program. The wearable device (CardioWatch 287-2), worn on patient's wrists, will provide clinicians with physiological information to better mirror the clinical oversight provided to an in-person CR program. Participants who choose to use the device will be asked to wear it daily. The clinical team will review weekly summary reports to help guide participant progress through the 13-week program. The primary objectives of this study are to: 1. Characterize participants (e.g., demographic health history, patient feedback) between those who choose to use the CardioWatch 287-2 device and those who do not. 2. Compare clinical outcomes between users and non-users of the device within the HEARTS in Sync program, by: 1. Tracking patient enrollment, attendance in virtual education sessions, and program completion rates, 2. Evaluating change in patient bloodwork outcomes, 3. Measuring change is physical ability, 4. Analyzing changes in eating behaviours, and 5. Examining quality of life using validated tools. 3. Asses the feasibility of the CardioWatch 287-2 for the HEARTS in Sync virtual CR program by: 1. Assessing device adherence 2. Reviewing patient feedback survey, and 3. Determining if clinician team were able to access and interpret data collected throughout the program The secondary objective of this study is to compare clinical outcomes of device users during the HEARTS in Sync program with patients who completed the on-site CR program. This research aims to better understand how a medical-grade device may improve virtual CR programming to extend clinical care to the community. As a result, this could lead to a more personalized care and better results for patients.

Waitlist Available
Has No Placebo

Mumford Professional Centre

Nicholas B Giacomantonio, Medical Doctor

Corsano Health B.V.

Have you considered Crestor clinical trials?

We made a collection of clinical trials featuring Crestor, we think they might fit your search criteria.
Go to Trials
Image of UA Collaboratory for Metabolic Disease Prevention & Treatment in Tucson, United States.

Community Health Intervention for Fatty Liver and Heart Diseases

18+
All Sexes
Tucson, AZ

CVD is the leading cause of death among individuals with MASLD, a risk factor for liver cancer. In Southern Arizona, CVD and cancer (including liver and gastric cancer) are among the leading causes of death for Mexican-origin adults.1 Given Mexican-origin adults' disproportionate burden of CVD-related mortality37 and higher rates of MASLD compared to other ethnic/racial groups; we urgently need to develop contextually tailored strategies for management of CVD risk factors and outcomes. Thus, the purpose of this study is to examine the acceptability and feasibility of a community health worker (CHW)-led intervention aimed to increase cardiovascular risk awareness and promote lifestyle modifications among Mexican-origin adults with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in the Southern Arizona region. The proposed project has the potential to improve health outcomes for this vulnerable population and contribute to the ACS-CHERC's overarching goal of improving health equity for Hispanic communities and family caregivers.

Recruiting
Has No Placebo

UA Collaboratory for Metabolic Disease Prevention & Treatment

Have you considered Crestor clinical trials?

We made a collection of clinical trials featuring Crestor, we think they might fit your search criteria.
Go to Trials
Image of UConn Health in Farmington, United States.

Digital Exercise Prescription Tool for Cardiovascular Disease

18 - 64
All Sexes
Farmington, CT

The investigators will conduct a feasibility and pilot efficacy randomized controlled trial to test the usability and user satisfaction of an evidence-based digital health tool the investigators developed for physicians to use to Prioritize Personalize Prescribe EXercise (P3-EX) to patients with cardiovascular disease (CVD) risk factors. The investigators will recruit 24 physicians from two local hospitals in CT, USA. Physicians will recruit two patients each (N=48) having CVD risk factors. Physicians will deliver a P3-EX exercise prescription (ExRx) to one of their patients (n=24) and the American College of Sports Medicine Physical Activity Vital Sign (ACSM-PAVS) ExRx to the other (n=24) in a random sequence crossover design. Physicians and patients will rate the feasibility and acceptability of each method using validated questionnaires. Patients will perform their prescribed ExRx for 12 weeks and complete a self-report exercise diary to monitor exercise adherence with virtual oversight from University of Connecticut (UConn) Graduate Research Assistants. Before and after the exercise intervention, the investigators will measure patient CVD risk factors and physical activity (PA) levels via accelerometry. The primary aim is to evaluate the feasibility and acceptability of P3-EX for physicians to use to prescribe exercise to patients with CVD risk factors, and the secondary aim is to explore the preliminary efficacy of P3-EX to improve patient CVD risk factors, PA levels, and exercise adherence. The investigators hypothesize P3-EX will be feasible for physicians to use to prescribe customized exercise routines for patients with CVD risk factors, and physicians and patients will be satisfied with P3-EX.

Waitlist Available
Has No Placebo

UConn Health (+2 Sites)

Linda S Pescatello, PhD

Have you considered Crestor clinical trials?

We made a collection of clinical trials featuring Crestor, we think they might fit your search criteria.
Go to Trials